KOSDAQBiotech & Pharma012790

Shinil Pharmaceutical

₩6,360▼ 0.63%2026-11-18 close
Market Cap
₩76.2B
Turnover
₩61,819,175
Volume
9.7K
Shares out.
12M
PER
14.7×
PBR
0.5×
EPS
₩446
Dividend Yield
2.91%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩190 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Up, Profits Down at Shinil Pharmaceutical

Shinil Pharmaceutical's Q3 2026 revenue rose 15.5% year on year, but operating profit fell 48.0%, so top-line recovery and profit recovery are moving in different directions.

  1. 1

    2025 revenue was KRW 80.6 billion, down 9.9% year on year, and operating profit was KRW 7.39 billion, down 51.5%, the smallest operating profit year in 2022-2025.

  2. 2

    Q3 2026 revenue of KRW 23.8 billion rose 15.5% year on year, while operating profit of KRW 1.39 billion fell 48.0%.

  3. 3

    According to a securities data provider, first-half 2026 standalone revenue rose 16.1% while operating profit fell 30.2%.

  4. 4

    Higher costs from drug price cut policies and tighter national health insurance finances were cited as factors that weighed on profitability.

  5. 5

    At year-end 2025, the debt ratio was 11.2%, with total equity of KRW 152.3 billion and total liabilities of KRW 17.1 billion.

02

Business structure

Shinil Pharmaceutical sells medicines in Korea and overseas, built on plaster and patch manufacturing know-how, and runs contract manufacturing for other pharmaceutical companies alongside. Its contract manufacturing work is described as covering products for about 80 companies.

By business segment, pharmaceuticals made up 96% of Q2 2026 revenue, cosmetics 2%, real estate 1%, and quasi-drugs 1%.

A product-level breakdown dated March 2026 puts general and prescription drugs, veterinary drugs and OEM work in an 'other' group at 72%, with Defenplasta at 9%, Harupenplasta at 7%, Lipicanjeong at 3%, and other items at 8%.

The two classifications differ and cannot be compared directly, but pharmaceuticals dominate under either view. New ventures include the Pharmtree functional cosmetics brand, with health functional foods, veterinary drugs and quasi-drugs also under way.

A 2024 first-half report put cosmetics and health functional foods together at 3.1% of revenue. In earlier reporting, the company said it planned to expand prescription drug sales and consider a larger CSO network. The largest shareholder group, led by Hong Jae-hyun with 22 others, holds 32.67%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩20.6B₩2.7B12.9%
2025Q4₩21.1B-₩400M−2.0%
2026Q1₩20.9B₩1.3B6.4%
2026Q2₩24.2B₩2.3B9.3%
2026Q3₩23.8B₩1.4B5.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩80B₩13.7B₩12.2B17.1%9.9%15.9%
2023₩89.1B₩14B₩13.6B15.7%10.1%13.0%
2024₩89.4B₩15.2B₩14.3B17.0%9.8%13.2%
2025₩80.6B₩7.4B₩7.5B9.2%4.9%11.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 80.0 billion in 2022 to KRW 89.1 billion in 2023, up 11.4%, and 2024 at KRW 89.4 billion, up 0.3%, was the largest year in 2022-2025. Revenue fell 9.9% to KRW 80.6 billion in 2025. The company attributed the fall in operating profit and net profit to lower revenue.

Operating profit rose from KRW 13.7 billion in 2022 to KRW 15.2 billion in 2024, then fell 51.5% to KRW 7.39 billion in 2025, the smallest year in the period. Operating margin went from 17.1% in 2022 and 17.0% in 2024 to 9.2% in 2025.

Profit attributable to controlling shareholders fell 47.3% to KRW 7.53 billion in 2025, and net profit including non-controlling interests was also KRW 7.53 billion. Operating cash flow dropped from KRW 22.7 billion in 2024 to KRW 11.6 billion in 2025.

Quarterly results moved from an operating profit of KRW 2.67 billion in Q3 2025 to an operating loss of KRW 424 million in Q4 2025, then back to an operating profit of KRW 1.33 billion in Q1 2026. Q2 2026 operating profit was KRW 2.26 billion on revenue of KRW 24.2 billion.

Q3 2026 revenue of KRW 23.8 billion rose 15.5% year on year, while operating profit of KRW 1.39 billion fell 48.0%. Profit attributable to controlling shareholders over the last four quarters totaled KRW 516 million. Revenue is recovering, but the margin pressure is reaching profit first. The cause of the Q4 2025 loss is a point to confirm in the annual report.

05

Industry analysis

Shinil Pharmaceutical operates in a market directly exposed to drug pricing policy. A securities data provider attributed the 2026 profitability decline to drug price cut policies and tighter national health insurance finances.

The same kind of source linked the weak first half of 2025 to government policy and rising competition. The company itself said consumer spending on over-the-counter products weakened with the economic slowdown. Its differentiation rests on specialized plaster and patch manufacturing.

The positioning is best read through its business structure and policy sensitivity. On the bullish side, contract manufacturing and patch technology support the revenue base despite policy risk. On the bearish side, policy costs have hit profit faster than revenue recovery has lifted it. The balance between these two forces is visible in future quarterly operating margins.

06

Outlook

The disclosed materials do not show a company-issued annual revenue or operating profit target. What is confirmed is that quarterly revenue has stayed between KRW 20.9 billion and KRW 24.2 billion since the start of 2026.

A securities data provider credited hospital distribution and stable CDMO orders for the revenue gains. New business lines are still small in revenue terms, and cosmetics and health functional foods would need sales channels and marketing spend to scale.

In earlier reporting the company said it was considering a larger CSO network to support prescription drug sales. The next regular filing is the 2026 annual report, where whether the operating margin recovers from 9.2% in 2025 is the key question. After that, the 2027 Q1 quarterly report will show whether CDMO revenue and the cost structure are changing.

07

Valuation

PER
14.7×
PBR
0.5×
ROE
3.4%
EPS
₩446
BPS
₩13,414
Dividend per share
₩190

The price-to-book ratio sits well below 1x, meaning the share price is trading far under net asset value. Earnings-based multiples reflect the profit decline since 2025, so how they read depends on the pace of earnings recovery. The dividend yield is well above the average of the KOSDAQ pharmaceutical sector.

The year-end 2025 cash dividend was confirmed at the regular shareholder meeting in March 2026. Dividend sustainability should be read alongside operating cash flow, which fell to KRW 11.6 billion in 2025. The low debt burden relative to assets is a supporting factor for dividend capacity. Valuation therefore turns on the pace of profit recovery and the direction of policy costs.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Revenue recovery

Quarterly revenue in 2026 has held between KRW 20.9 billion and KRW 24.2 billion. Q2 revenue rose 16.0% from the prior quarter, and Q3 revenue rose 15.5% year on year. A securities data provider credited hospital distribution and stable CDMO orders. If the top line holds, there is room for the operating margin to recover.

Balance sheet capacity

At year-end 2025, the debt ratio was 11.2%, with total liabilities of KRW 17.1 billion and total equity of KRW 152.3 billion. Operating cash flow stayed positive at KRW 11.6 billion in 2025. The low leverage is cited on the bull side as a buffer if the pricing environment shifts.

Dividend and shareholder base

The year-end 2025 cash dividend was approved at the March 2026 shareholder meeting. The dividend yield is well above the KOSDAQ pharmaceutical sector average. The largest shareholder group holds 32.67%.

09

Bear factors

Falling operating profit

Operating profit fell 51.5% to KRW 7.39 billion in 2025, and operating margin dropped to 9.2% from 17.0% in 2024. Q4 2025 turned to an operating loss of KRW 424 million. Q3 2026 operating profit of KRW 1.39 billion fell 48.0% year on year. Profit attributable to controlling shareholders over the last four quarters totaled KRW 516 million.

Policy cost pressure

A securities data provider said rising costs from drug price cuts and tighter health insurance finances weighed on profitability. The weak first half of 2025 was also attributed to government policy and competition. The bear case rests on policy changes reaching costs faster than revenue.

Limited diversification

In a 2024 first-half report, cosmetics and health functional foods together accounted for only 3.1% of revenue. Pharmaceuticals made up 96% of Q2 2026 revenue, so the business remains concentrated. Until new ventures become meaningful earnings sources, diversifying policy risk will be hard.

10

Risk factors

Policy and drug pricing risk

Drug price policy changes and tighter health insurance finances are cost factors the company cannot easily control. Both the 2025 profit decline and the first-half 2026 operating profit decline are linked to this trend. How policy changes flow into future results is the next point to track.

Earnings volatility

Quarterly operating profit has swung widely, from KRW 2.67 billion in Q3 2025 to an operating loss of KRW 424 million in Q4 2025. Even after the Q1 2026 return to profit, Q3 2026 operating profit fell 48.0% year on year. Large quarterly swings make the earnings trend harder to read.

Business concentration and cash flow

Pharmaceuticals account for 96% of revenue, and the largest shareholder group holds 32.67%. How lower cash generation affects new business investment and dividend capacity is a point to track through disclosures.

11

What to watch next

  1. December 31, 2026

    Fiscal year-end for 2026. Q4 results are finalized in the annual report rather than a separate quarterly release, so whether a quarterly loss recurs as it did in Q4 2025 is the point to confirm.

  2. Early March 2027 (based on last year's filing timing)

    Expected filing of the 2026 annual report. Whether operating margin recovers from 9.2% in 2025 and how drug pricing policy affected results will be confirmed in the reported figures.

  3. Late March 2027 (based on last year's shareholder meeting date)

    The regular shareholder meeting approves the 2026 financial statements and dividend. The dividend scale and shareholder return direction will be settled there.

  4. Mid-May 2027 (based on last year's Q1 report timing)

    The Q1 2027 quarterly report. It will show whether the Q1 2026 return to profit holds and how CDMO revenue and the cost structure are changing.

  5. Mid-August 2027 (based on last year's half-year report timing)

    First-half 2027 results. Whether operating profit breaks out of the first-half 2026 decline is the point to confirm.

12

Overall view

Shinil Pharmaceutical's quarterly revenue has held between KRW 20.9 billion and KRW 24.2 billion in 2026, showing a recovery in the top line. Operating profit, however, fell 51.5% to KRW 7.39 billion in 2025, and Q3 2026 operating profit fell 48.0% year on year.

Revenue gains not turning into profit gains are the central issue in current results. Higher costs from drug price cuts and tighter health insurance finances are cited as the background to the margin decline. On the balance sheet, the year-end 2025 debt ratio was 11.2% with total equity of KRW 152.3 billion.

A year-end 2025 cash dividend was confirmed, but it should be read alongside the drop in operating cash flow. The business remains concentrated in pharmaceuticals at 96% of revenue, with cosmetics and health functional foods still small.

The next points to confirm are the 2026 annual report and the 2027 regular shareholder meeting, and whether the operating margin recovers from 9.2% in 2025.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.wisereport.co.kr
  2. jobplanet.co.kr
  3. comp.fnguide.com
  4. butler.works
  5. jobkorea.co.kr
  6. ibtomato.com
  7. medipana.com
  8. m.news.nate.com
  9. m.dailypharm.com
  10. newsthevoice.com
  11. scoreport.kr
  12. kr.investing.com
  13. news.nate.com
  14. accidentalorder.com
  15. bbn.kiwoom.com
  16. news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis